pathway visibl growth rebound tax
net dbt
lot question limit answer head
cardin result surfac first look better underli
perform highlight continu challeng busi
well new uncertainti creat profit growth question within medic
segment particular pharma segment ebit came better
necessarili new surpris overal ebit perform remain pressur
contract renew ad anoth headwind head meanwhil move
piec tax rate aid creat anoth uncertainti pure ep
growth beyond biggest issu remain
number piec eventu lead sustain profit perform
simpli visibl feel comfort model trajectori
therefor reiter under-perform rate price object
price-to-earnings unchang stock still remain low end histor rang
see identifi catalyst drive type near-term multipl expans
increas ep reduc
follow earn increas ep reduc
ep increas account beat
well adjust impli higher tax rate assum updat guidanc
meanwhil lower ep driven lower medic revenu well lower
upcom event catalyst
given expect pace ebit ramp last fiscal quarter key upcom
catalyst anyth give greater clariti ramp includ
manag commentari intra-quart pace growth well
addit data point brand/gener price cours quarter also
evolv rebat model focu updat could impact role
distributor model could serv catalyst lead formal
guidanc expect call earli august
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug medic product
two-third profit pharmaceut
busi nearli one-third medic
support retail/mail/hospital/physician client
well drug manufactur medic busi
manufactur portfolio medic
product distribut brand-nam product
hospit physician compani base
under-perform rate driven increasingli
competit market compani core
busi pharmaceut medic devic
limit near-term offset think market
pharmaceut distribut remain
challeng near term histor upsid driver
red oak sourc benefit slow
medic cordi platform like support
solid growth ex-u see price volum
revenu oper earn line expect
ep guidanc rais
extend distribut agreement begin juli
gener program perform consist prior quarter
strong contribut specialti nuclear
disappoint perform quarter
would like see better perform global cost structur
move sens urgenc issu medic segment
patient recoveri tsa exit nearli complet
cordi stabil program track
continu execut growth strategi return cash sharehold
segment profit ahead expect decreas due
weaker gener last year custom renew less off-set
improv servic level trend reach month high
strong growth strateg account
well
anyth call
contract four year period
new price goe effect juli
medic segment challeng busi
largest driver perform cardin brand product
normal market dynam compani overcom around
mix/volum compani abl off-set dynam
addit challeng suppli chain cost
integr work result back order
cardin health brand product compani speak suppli chain
cost process current competit landscap
cost challeng span area
manufactur perspect commod cost headwind
thing caus challeng suppli chain
caus issu compani experienc higher cost
competit landscap remain similar
tsa exit littl lumpier compani expect
creat servic level challeng compani still
work
seen challeng cost structur commod fx cost
initi taken longer get
pharma segment gener perform weak drive weak
gener program signific headwind
compani scale back cost reduct due perform medic
track ahead plan
save compani redirect fix
short-term challeng medic
compani disciplin
gener spread one cah peer spoke pharma oper incom growth
see improv
spread consist prior quarter
see consist net headwind past quarter
see headwind reduc
medic one-tim
guidanc reduct reflect challeng compani seen
second half year rel consist first half
provid clariti next year
compani doesnt typic provid commentari next fiscal
year quarter
pharma segment impli high end oper
incom y/i versu low end would swing
factor
driver compani throughout year
strong growth specialti help compani context drive
driver overal market growth
price object ep multipl five-year
averag discount incorpor margin price pressur
pharmaceut segment slow brand inflat increas competit
downstream independ buy group discount medic segment
incorpor grow risk non-tradit distributor
upsid risk po potenti volum pickup increas buyside/sellsid
spread faster-than-expect contribut recent acquir medic
busi capit deploy downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market lack
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
